Dedication
Ronald Hoffman(Icahn School of Medicine at Mount Sinai), Syed A. Abutalib(Cancer Treatment Centers of America), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Leslie E. Silberstein(Boston Children's Hospital), Jeffrey I. Weitz(McMaster University Medical Centre), John Anastasi(Brown University), Edward J. Benz(Brigham and Women's Hospital), Helen E. Heslop(Texas Children's Hospital)
Cited by 1
Related Papers
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
|New England Journal of Medicine|2017|1.1k
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
|Journal of Clinical Investigation|1990|1.1k